Open an account

First Trust NYSE Arca Biotechnology Index Fund

FBT · ETF

$269.25−$3.43 (−1.26%)TodayMarket closed ·
Prev close $272.68

About FBT

FBT was created on 2006-06-19 by First Trust. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 2901.09m in AUM and 31 holdings. FBT tracks an equal-weighted index of US biotechnology stocks.

Issuer
First Trust
Tracks
NYSE Arca Biotechnology Index
Expense ratio
0.55%
Assets under management
$3.01B
Inception
Jun 19, 2006
Asset class
Equity
Website
ftportfolios.com

FBT key statistics

Market cap
0
Price-earnings ratio
0.00
Average volume
100.26K
Volume
60.23K
Open price
$271.54
High today
$271.54
Low today
$268.02
52 Week high
$275.23
52 Week low
$186.20

First Trust NYSE Arca Biotechnology Index Fund (FBT) at a glance

As of Oct 23, 2026, First Trust NYSE Arca Biotechnology Index Fund (FBT) shares are priced at $269.25, giving the company a market cap of 0 and a price-to-earnings ratio of 0.00.

Today the fund has traded between $268.02 and $271.54. The current price is 0.5% above the day's low and 0.8% below its high.

Volume so far is 60.23K shares, below the average of 100.26K shares a day.

Over the past year First Trust NYSE Arca Biotechnology Index Fund has ranged from $186.20 to $275.23, and now sits 93% of the way up that range.

FBT news

  • Chandrima Sanyal

    Cathie Wood Loads Up On Biotech: 5 ETFs Holding Her Latest Bets

  • Vandana Singh

    Why Is Natera Stock Gaining Tuesday?

  • Vandana Singh

    Moderna's Legal Hit Steals Spotlight From Strong Sales

  • Vandana Singh

    FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars

  • Vandana Singh

    Illumina Gets Medicare Boost for Cancer Test, Shares Climb

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.